Therefore, we find that strong (2-fold) elevation of GDF15 acts as an effective diagnostic biomarker distinguishing CMT patients from both controls and from two other muscle wasting disorders. The gene discussed is GDF15; the disease is Charcot-Marie-Tooth disease.